Jennifer H Gunter

List of Publications by Year
in descending order

35 papers	1,282 citations	471371 17 h-index	454834 30 g-index
39 all docs	39 docs citations	39 times ranked	2342 citing authors

#	Article	IF	Citations
1	Isomeric lipid signatures reveal compartmentalized fatty acid metabolism in cancer. Journal of Lipid Research, 2022, 63, 100223.	2.0	10
2	TGFÎ² and CIS Inhibition Overcomes NK-cell Suppression to Restore Antitumor Immunity. Cancer Immunology Research, 2022, 10, 1047-1054.	1.6	11
3	The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype. PeerJ, 2021, 9, e10280.	0.9	5
4	Leptin antagonism inhibits prostate cancer xenograft growth and progression. Endocrine-Related Cancer, 2021, 28, 353-375.	1.6	6
5	Allele-Specific MicroRNA-Mediated Regulation of a Glycolysis Gatekeeper PDK1 in Cancer Metabolism. Cancers, 2021, 13, 3582.	1.7	8
6	Studying the Metabolism of Epithelial-Mesenchymal Plasticity Using the Seahorse XFe96 Extracellular Flux Analyzer. Methods in Molecular Biology, 2021, 2179, 327-340.	0.4	7
7	Synthesis of a Unique Psammaplysin F Library and Functional Evaluation in Prostate Cancer Cells by Multiparametric Quantitative Single Cell Imaging. Journal of Natural Products, 2020, 83, 2357-2366.	1.5	13
8	Revisiting Glycogen in Cancer: A Conspicuous and Targetable Enabler of Malignant Transformation. Frontiers in Oncology, 2020, 10, 592455.	1.3	24
9	Class IIa Histone Deacetylases Drive Toll-like Receptor-Inducible Glycolysis and Macrophage Inflammatory Responses via Pyruvate Kinase M2. Cell Reports, 2020, 30, 2712-2728.e8.	2.9	51
10	Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma. Cancers, 2020, 12, 869.	1.7	7
11	Insulin Enhances Migration and Invasion in Prostate Cancer Cells by Up-Regulation of FOXC2. Frontiers in Endocrinology, 2019, 10, 481.	1.5	22
12	Emergence of MicroRNAs as Key Players in Cancer Cell Metabolism. Clinical Chemistry, 2019, 65, 1090-1101.	1.5	53
13	A molecular portrait of epithelialâ€“mesenchymal plasticity in prostate cancer associated with clinical outcome. Oncogene, 2019, 38, 913-934.	2.6	76
14	Bclâ€2 inhibitors enhance FGFR inhibitorâ€induced mitochondrialâ€dependent cell death in FGFR2â€mutant endometrial cancer. Molecular Oncology, 2019, 13, 738-756.	2.1	12
15	Abstract LB-B31: FGFR inhibition in endometrial cancer induces caspase-independent cell death that can be augmented with ABT-737. , 2018, , .		0
16	Abstract 2452: Dysregulated expression of the human long noncoding RNAGHSROSmay influence prostate cancer progression and resistance to docetaxel. , 2018, , .		0
17	Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene, 2017, 36, 3417-3427.	2.6	68
18	PNFBA-08 NOVEL IN VITRO ORGANOID TECHNOLOGY TO FACILITATE A PRECISION MEDICINE APPROACH IN THEÂMANAGEMENT OF MEN WITH BIOCHEMICAL RECURRENCE OF PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.2	0

#	Article	IF	Citations
19	Abstract 3442: The long non-coding RNAGHSROSmediates expression of genes associated with tumor growth, metastasis and adverse disease outcome. , 2017, , .		0
20	Abstract 4909: Androgen targeted therapy induces ZEB1 expression and is associated with suppression of androgen signalling and therapy resistance. , 2017, , .		1
21	MP07-18 PERSISTENCE OF CIRCULATING TUMOUR CELLS (CTCS) IN MEN TREATED WITH ANDROGEN DEPRIVATION THERAPY CAN BE USED TO ENRICH AND PROPAGATE TEMPORARY PERSONALIZED CELL LINES. Journal of Urology, 2016, 195, .	0.2	0
22	Repositioning â€œoldâ€•drugs for new causes: identifying new inhibitors of prostate cancer cell migration and invasion. Clinical and Experimental Metastasis, 2016, 33, 385-399.	1.7	21
23	Adverse effects of androgenâ€deprivation therapy in prostate cancer and their management. BJU International, 2015, 115, 3-13.	1.3	109
24	The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer. Oncotarget, 2014, 5, 9362-9381.	0.8	111
25	IGF2 increases de novo steroidogenesis in prostate cancer cells. Endocrine-Related Cancer, 2013, 20, 173-186.	1.6	48
26	New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication. International Journal of Cell Biology, 2013, 2013, 1-13.	1.0	30
27	The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer. Advances in Urology, 2012, 2012, 1-11.	0.6	24
28	Different Characteristics and Nucleotide Binding Properties of Inosine Monophosphate Dehydrogenase (IMPDH) Isoforms. PLoS ONE, 2012, 7, e51096.	1.1	71
29	Insulin Increases De Novo Steroidogenesis in Prostate Cancer Cells. Cancer Research, 2011, 71, 5754-5764.	0.4	97
30	The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation. Diabetologia, 2010, 53, 321-330.	2.9	192
31	Inhibition of inosine monophosphate dehydrogenase reduces adipogenesis and diet-induced obesity. Biochemical and Biophysical Research Communications, 2009, 386, 351-355.	1.0	8
32	Characterisation of inosine monophosphate dehydrogenase expression during retinal development: Differences between variants and isoforms. International Journal of Biochemistry and Cell Biology, 2008, 40, 1716-1728.	1.2	56
33	Adverse physicochemical properties of tripalmitin in beta cells lead to morphological changes and lipotoxicity in vitro. Diabetologia, 2005, 48, 1819-1829.	2.9	106
34	Islet amyloid polypeptide gene promoter polymorphisms are not associated with Type 2 diabetes or with the severity of islet amyloidosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1740, 74-78.	1.8	12
35	Apolipoprotein E genotype, islet amyloid deposition and severity of Type 2 diabetes. Diabetes Research and Clinical Practice, 2003, 60, 105-110.	1.1	18